Evidence map›Paper›PMID 25365067›Full record

Trial reportBone marrow transplantation2015

Successful early unmanipulated haploidentical transplantation with reduced-intensity conditioning for primary graft failure after cord blood transplantation in hematologic malignancy patients.

B L Tang, X Y Zhu, C C Zheng, H L Liu, L Q Geng, X B Wang, K Y Ding, W Yao, J Tong, K D Song and 3 more

Abstract readClinical Trial
PubMed Publisher
In one paragraph

Trial report in Bone marrow transplantation, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
1.4field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 18 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 2 institutions in 1 country.

B L TangDepartment of Hematology, Anhui Provincial Hospital, Anhui Medical University, Hefei, China.
X Y ZhuDepartment of Hematology, Anhui Provincial Hospital, Anhui Medical University, Hefei, China.
C C ZhengDepartment of Hematology, Anhui Provincial Hospital, Anhui Medical University, Hefei, China.
H L LiuDepartment of Hematology, Anhui Provincial Hospital, Anhui Medical University, Hefei, China.
L Q GengDepartment of Hematology, Anhui Provincial Hospital, Anhui Medical University, Hefei, China.
X B WangDepartment of Hematology, Anhui Provincial Hospital, Anhui Medical University, Hefei, China.
K Y DingDepartment of Hematology, Anhui Provincial Hospital, Anhui Medical University, Hefei, China.
W YaoDepartment of Hematology, Anhui Provincial Hospital, Anhui Medical University, Hefei, China.
J TongDepartment of Hematology, Anhui Provincial Hospital, Anhui Medical University, Hefei, China.
K D SongDepartment of Hematology, Anhui Provincial Hospital, Anhui Medical University, Hefei, China.
L ZhangDepartment of Hematology, Anhui Provincial Hospital, Anhui Medical University, Hefei, China.
P QiangDepartment of Hematology, Anhui Provincial Hospital, Anhui Medical University, Hefei, China.
Z M SunDepartment of Hematology, Anhui Provincial Hospital, Anhui Medical University, Hefei, China.
Anhui Medical University · CNAnhui Provincial Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Primary graft failure (pGF) is a frequent complication following cord blood transplantation (CBT). For those patients who will not experience autologous recovery, salvage transplantation should be performed as early as possible. However, standardized treatment protocols for pGF, such as the optimal stem cell source, preparative regimen and the ideal time for salvage transplantation, have yet to be determined. Therefore, we analyzed 17 hematologic malignancy patients who received unmanipulated haploidentical peripheral blood (PB) and BM transplantation with reduced-intensity conditioning (RIC) as a salvage therapy for pGF after CBT. The median interval between the two transplantations was 38 days. The RIC regimen for salvage transplantation consisted of fludarabine, antithymocyte globulin, CY and low-dose TBI. The neutrophil and plt engraftments were achieved in 14 (82.4%) and 13 (76.4%) patients, respectively. The cumulative incidences of grades II-IV and grades III-IV aGVHD were 35.3% and 17.6%, respectively. The cumulative incidence of chronic GVHD was 29.4%. After a median follow-up of 43 months, 10 of 17 patients remained alive in CR. The cumulative incidence of TRM at 180 days was 29.4%. The probability of 3-year OS and leukemia-free survival was 57.5%. Our results show that unmanipulated haploidentical PB and BM transplantation under a RIC regimen is an effective treatment for pGF after CBT.

Indexed as

Bone Marrow TransplantationCord Blood Stem Cell TransplantationGraft SurvivalPeripheral Blood Stem Cell TransplantationAdolescentAdultAllograftsChildChild, PreschoolFemaleFollow-Up StudiesGraft RejectionHematologic NeoplasmsHumansMaleMiddle AgedMyeloablative Agonists

Identifiers

PMID25365067
OpenAlexW2058009140

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.